Shots:

• The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] in 8-500+ patients with mod. to sev. COPD and a history of exacerbation(s) in the previous year- receiving at least two inhaled maintenance treatments at entry into the study
• Results: 24% reduction in exacerbations; 46% reduction in the risk of all-cause mortality when compared with Bevespi Aerosphere- showed a 13% reduction in exacerbations compared with PT009. Additionally- demonstrated a reduction in the rate of mod. or sev. exacerbations at the half dose of budesonide
• Breztri Aerosphere is an approved therapy in Japan and China for patients with COPD and is under regulatory review in the US and EU. As per the agreement to acquire Pearl Therapeutics- AstraZeneca will pay $150M as milestone upon US approval of the therapy for COPD

Click here to read full press release/ article 

Ref: AstraZeneca | Image: Pharmaceutical Technology